top of page
About
Home
Team
Partnerships
Send us your innovation
Contact
EN
JP
We are an asset-light, emerging commercial-stage biopharma and MedTech operating company that in-licenses early, de-risked assets to commercialize in Japan and the APAC region
News & Updates
Expanding Generational Health Access in Japan: A Strategic Collaboration Oct 2, 2025
Indonesia Inovasi Sehat and HekaBio Sign Strategic Agreement to Advance Healthcare Innovation in Indonesia Oct 1, 2025
NKGen and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan July 21, 2025
HekaBio Enters Strategic Partnership with Alfresa Holdings Corporation June 16, 2025
HekaBio Welcomes Deron Wolfe as Chief Financial Officer June 10, 2025
Rodney Kelly Joins HekaBio as Chief Growth Officer April 1, 2025
Dr. Yoshimura at the Institute of Science Tokyo has published "Efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for head and neck cancer recurrence after radiotherapy." Feb. 26
Limaca's Precision-GI™ Enters US Market Feb. 20, 2025
Limaca's Precision-GI™ Granted CMS Transitional Pass-Through (TPT) Payment Nov. 8, 2024
1
2
3
4
bottom of page
